ENSC ENSC
Company Profile ↓Company Overview
ENSC (ENSC) is a publicly traded company listed on with a market capitalization of $1.65M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.10.
Recent Developments
- Dec 2025 Revenue of $5.07M (-2.8% YoY); net profit $-10.18M.
- Trailing 12 Months Year-on-year growth — revenue -2.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 5.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 5.21% |
| 1 Year: | -2.75% |
Stock Price Performance
| 1 Year: | -83.16% |
| 6 Months: | -40.66% |
| 3 Months: | -9.50% |
| 1 Month: | +31.16% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)66.94 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 85.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 444.52K | 1.20M | 603.10K | 207.47K | 279.35K | 789.63K | 490.47K | 435.38K | 305.72K | 181.80K | 3.42M | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.97M | 1.75M | 3.74M | 2.78M | 3.56M |
| Operating Income | -170.13K | -311.54K | -248.19K | -189.17K | -625.94K | -584.42K | -915.18K | 139.08K | -404.77K | -524.27K | -412.62K | -16.89M | -4.80M | -7.06M | -6.16M | -2.56M | -2.29M | -2.71M | -1.84M | -1.96M | 644.75K | - | -1.97M | -1.75M | -3.74M | -2.78M | -3.56M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.94M | -1.73M | -3.72M | -2.76M | -3.55M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.86K | 3.16K | 6.37K | 5.38K | 3.92K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.95M | -1.73M | -3.73M | -2.77M | -3.56M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | 406.07K | 415.11K | 577.65K | 775.91K | 418.90K | 489.72K | 1.79M | -704.50K | 1.57M | -1.71M | -935.54K | -17.16M | - | - | - | - | - | - | - | - | - | - | -1.95M | -1.73M | -3.73M | -2.77M | -3.56M |
| Diluted EPS | - | - | - | - | - | - | - | - | 0.09 | - | - | -0.71 | - | -56.49 | -61.58 | -2.08 | -0.98 | -0.87 | -8.21 | -3.35 | 1.00 | - | -1.39 | -0.79 | -1.29 | -0.75 | -0.52 |
| R&D Expense | - | - | - | - | - | - | - | 1.40M | 892.99K | 284.38K | 463.22K | 1.71M | 3.14M | 5.31M | 4.76M | 1.80M | 1.64M | 1.91M | 778.90K | 947.23K | 1.69M | - | 1.89M | 1.92M | 2.95M | - | 3.35M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 3.93M | 3.53M | 2.52M | 2.23M | 5.21M | 5.07M |
| Operating Income | -959.24K | -3.33M | -1.61M | -19.87M | -24.22M | -10.72M | -6.73M | -10.24M |
| Net Income | 2.12M | 365.95K | 2.40M | -29.89M | -25.09M | -10.63M | -7.99M | -10.18M |
| Diluted EPS | - | - | 0.00 | -1.48 | -139.42 | -70.40 | -11.45 | -3.98 |
| R&D Expense | - | - | 4.39M | 4.69M | 19.84M | 7.59M | 7.22M | 10.38M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 202.43M | 204.83M | 196.51M | 351.81K | - | 5.89M | 2.71M | 5.60M | 7.45M |
| Current Assets | - | - | - | - | - | 5.30M | 2.29M | 5.34M | 7.24M |
| Cash & Equivalents | - | - | - | 194.21K | - | 3.15M | 1.12M | 3.50M | 4.31M |
| Inventory | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | 276.82K | 97.56K | 124.11K | 420.35K |
| Total Liabilities | 7.16M | 7.44M | 10.34M | 7.01M | - | 9.91M | 3.36M | 2.22M | 4.57M |
| Current Liabilities | 156.24K | 437.89K | 2.77M | 7.01M | - | 9.46M | 3.33M | 2.21M | 4.57M |
| Long Term Debt | - | - | - | - | 4.44M | 140.15K | - | - | - |
| Total Debt | - | - | - | - | - | 4.43M | 854.70K | 301.66K | 306.71K |
| Total Equity | 5.00M | 5.00M | 5.00M | -6.44M | - | -3.71M | -322.86K | 3.71M | 3.21M |
| Shares Outstanding | - | - | - | - | - | 35.63K | 209.74K | 1.36M | 4.57M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.24M | -1.42M | -1.25M | -8.24M | -17.89M | -10.78M | -7.50M | -7.81M |
| Investing Cash Flow | 838.59K | 11.85M | 183.40M | - | 4.50K | - | - | -123.64K |
| Financing Cash Flow | -32.00K | -11.03M | 1.10M | 20.31M | 8.77M | 8.76M | 9.88M | 8.74M |
| Capital Expenditure | - | - | - | - | - | - | - | -123.64K |
| Free Cash Flow | - | - | - | - | - | - | - | -7.93M |
| Share Buybacks | - | 11.58M | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -41.0% | -562.7% | -959.9% | -480.5% | -129.2% | -202.1% |
| Net Margin % | - | - | 61.2% | -846.4% | -994.1% | -476.4% | -153.3% | -200.8% |
| ROE % | 42.4% | 7.3% | -37.3% | - | 675.3% | 3,291.2% | -215.4% | -316.6% |
| ROCE % | -0.5% | -1.7% | 24.2% | - | 676.8% | 1,715.2% | -198.5% | -355.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ENSC
Ensysce Biosciences Receives Final $5.3 Million NIDA Funding Installment for PF614-MPAR Development
Ensysce Biosciences (NASDAQ:ENSC) has received a $5. 3 million award from the National Institute on Drug Abuse (NIDA), completing a multi-year federal grant totaling $15.
Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant
Funds Advance FDA-Designated Breakthrough Therapy First-in-Class Opioid with Oral Overdose-Protection SAN DIEGO, CA / ACCESS Newswire / July 14, 2026 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage ph…
ENSC Receives Vital Funding for Drive to Commercialization
By Brad Sorensen, CFA NASDAQ: ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ: ENSC) is developing what could become a new generation of prescription medicines designed to maintain the effectiveness of powerful pain medi…
Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth
VANCOUVER, British Columbia, July 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology…
Postoperative Pain - Pipeline Insight, 2026 Now Available; Comprehensive Profiles of 40+ Key Players Including Ensysce Biosciences and Allay Therapeutics
The report highlights significant market opportunities in postoperative pain treatment through the development of innovative therapies by 40+ companies. Novel drug candidates in various trial stages, like PF614 and ATX101, promise longer pa…
Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study
~ ~ Advances First-in-Class, Breakthrough Therapy-Designated Opioid Engineered to Protect Against Oral Overdose ~ ~ SAN DIEGO, CA / ACCESS Newswire / June 26, 2026 /Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a cli…
ENSC — Frequently Asked Questions
What is the current share price of ENSC?
As of 2026-08-05 17:25 PDT, ENSC trades at $0.36 on NASDAQ/NYSE. Its 52-week range is $0.25 to $2.57.
What is the market capitalisation of ENSC?
ENSC has a market capitalisation of $1.65M on NASDAQ/NYSE.
What is the P/E ratio of ENSC?
ENSC trades at a trailing price-to-earnings (P/E) ratio of -0.09. Its price-to-book (P/B) ratio is 0.51.
Is ENSC a good stock to buy?
This page provides a data-driven analysis of ENSC, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.